Edition:
United States

Galectin Therapeutics Inc (GALT.OQ)

GALT.OQ on NASDAQ Stock Exchange Capital Market

0.88USD
5 Dec 2016
Change (% chg)

$0.01 (+1.15%)
Prev Close
$0.87
Open
$0.85
Day's High
$0.88
Day's Low
$0.85
Volume
16,817
Avg. Vol
81,424
52-wk High
$3.05
52-wk Low
$0.49

GALT.OQ

Chart for GALT.OQ

About

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company's drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. It uses naturally... (more)

Overall

Beta: 2.01
Market Cap(Mil.): $28.38
Shares Outstanding(Mil.): 29.40
Dividend: --
Yield (%): --

Financials

  GALT.OQ Industry Sector
P/E (TTM): -- 42.21 29.87
EPS (TTM): -0.83 -- --
ROI: -135.26 -1.09 14.95
ROE: -293.75 -2.39 16.29

BRIEF-Galectin Therapeutics announces positive new psoriasis and atopic dermatitis clinical data

* Galectin Therapeutics announces positive new psoriasis and atopic dermatitis clinical data, seeking strategic partnerships for therapy of severe skin diseases Source text for Eikon: Further company coverage:

Nov 10 2016

BRIEF-Galectin Therapeutics Q3 loss per share $0.19

* Galectin Therapeutics Inc- on track for reporting of top-line results in december of 2017 for nash-cx trial

Nov 08 2016

BRIEF-Galectin says announces top-line data from exploratory phase 2A pilot trial (NASH-FX)

* Galectin therapeutics announces top-line data from exploratory phase 2a pilot trial (nash-fx) with gr-md-02 in nash patients with advanced fibrosis

Sep 27 2016

BRIEF-Galectin Therapeutics posts results from extended psoriasis clinical trial - SEC Filing

* Says announces results from 12-week extension of phase 2A psoriasis clinical trial - SEC Filing

Aug 25 2016

BRIEF-Galectin Therapeutics Q2 loss per share $0.20

* Galectin therapeutics reports second quarter 2016 financial results and provides business update

Aug 09 2016

BRIEF-Galectin Therapeutics quarterly loss per share $0.20

* Believes it has sufficient cash to fund currently planned operations and research, development activities through June 30, 2017

Aug 09 2016

Competitors

Earnings vs. Estimates